Buy Rating for Regeneron Pharmaceuticals Amidst EU Approval of Dupixent and Positive Market Outlook
Regeneron Pharmaceuticals Analyst Ratings
Canaccord Genuity Maintains Buy on Regeneron Pharmaceuticals, Maintains $1152 Price Target
Argus Adjusts Price Target on Regeneron Pharmaceuticals to $1,170 From $1,060, Buy Rating Maintained
RBC Capital Reiterates Outperform on Regeneron Pharmaceuticals, Maintains $1229 Price Target
Regeneron Pharmaceuticals Analyst Ratings
Regeneron Pharmaceuticals Analyst Ratings
JPMorgan Adjusts Price Target on Regeneron Pharmaceuticals to $1,150 From $1,050
Wells Fargo Adjusts Price Target on Regeneron Pharmaceuticals to $1,125 From $1,050
Regeneron Pharmaceuticals Analyst Ratings
Regeneron Pharmaceuticals Analyst Ratings
Jefferies Raises Regeneron Pharmaceuticals' Price Target to $1,125 From $1,115
Piper Sandler Adjusts Price Target on Regeneron Pharmaceuticals to $1,000 From $1,000.25
Jefferies Raises Regeneron Pharmaceuticals' Price Target to $1,115 From $1,060
Regeneron Pharmaceuticals Analyst Ratings
UBS Raises Regeneron Pharmaceuticals Price Target to $1,124 From $1,099, Maintains Buy Rating
Cantor Fitzgerald: Regeneron Pharmaceuticals (REGN.US) rating was reaffirmed, adjusted from neutral to neutral, with a target price of $925.00.
Regeneron Pharmaceuticals Analyst Ratings
Goldman Sachs Adjusts Price Target on Regeneron Pharmaceuticals to $1,180 From $1,126
RBC Cuts Price Target on Regeneron Pharmaceuticals to $1,185 From $1,189